Navigation Links
TGen/Mayo Clinic/Arizona Cancer Center study finds gene associated with aggressive skin cancer
Date:9/28/2010

PHOENIX, Ariz. Sept. 28, 2010 The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Arizona Cancer Center, Mayo Clinic and the Translational Genomics Research Institute (TGen).

Targeting INPP5A could provide physicians with better ways to prevent and treat cutaneous squamous cell carcinoma, or SCC, a skin cancer that often spreads to other parts of the body, according to a scientific paper published today in the journal Cancer Prevention Research.

"Loss of INPP5A can be detected in most primary SCC tumors and even in actinic keratoses, or AK, the earliest stage in SCC development," said Aleksandar Sekulic, M.D., Ph.D., an Assistant Professor of Dermatology at Mayo Clinic in Arizona, and the study's lead author. "Importantly, further reduction of INPP5A was detected as a subset of SCC tumors progressed from primary to metastatic stage."

More than 1 million non-melanoma skin cancers are diagnosed annually in the U.S., making these the most common type of cancer and the fifth most costly cancer type in the Medicare population, those Americans age 65 and older. The vast majority of non-melanoma skin cancers are basal cell carcinoma and SCC.

"At present, our ability to assess who is at risk for SCC and our ability to treat the disease, especially in its aggressive forms, is clearly inadequate," said Dr. Jeffrey Trent, President and Research Director of TGen and one of the study's authors. "Without question, additional investigations into INPP5A are warranted. Studies like this are critical if we are to ever get a handle on this all-too-common type of skin cancer."

The study used TGen's advanced genomic technologies to analyze 40 skin tissue samples that ranged from normal skin to highly invasive SCC. Specifically, researchers used a technique called high-resolution array-based comparative genomic hybirdization to identify genetic deletions in a portion of DNA that normally harbors the INPP5A gene.

INPP5A, or inositol polyphosphate-5-phosphatase, interacts within the chemical pathways of cells to limit their proliferation, suggesting that this gene may play a key role as a tumor suppressor. In other studies, the loss of genetic material in the chromosome that includes INPP5A has been associated with brain tumors and leukemias.

Genetic mutations contribute to the development and progression of cancer by either stimulating cells to multiply too rapidly, or interfering with normal processes that allow them to die off, according to the paper, Loss of Inositol Polyphosphate-5-Phosphatase is an Early Event in Development of Cutaneous Squamous Cell Carcinoma.

"Understanding the precise mechanisms of INPP5A loss, and exploring the connection between INPP5A and uncontrolled cellular proliferation, could provide us with new insights," said Dr. Michael Bittner, Co-Director of TGen's Computational Biology Division, and the study's senior author. "Continuing studies could lead to new drug targets that could contribute to better treatments for patients with SCC, and some day perhaps even help prevent this type of skin cancer."

Tissue samples and research collaborations for the study were provided by: the University of Arizona's Arizona Cancer Center in Tucson; the Southern Arizona Veterans Affairs Health Care System in Tucson; Loyola University Medical Center in Chicago; and Mayo Clinic.

Dr. David S. Alberts, Director of the Arizona Cancer Center, is the Principal Investigator for a cancer prevention grant from the National Institutes of Health, which provided the main funding for the study.

"Observed deletions in INPP5A represents a highly selected, non-random genetic event in SCC, giving researchers confidence that this is a biomarker with great potential for clinical study and patient benefit," said Dr. Alberts, another author of the paper and a Regents Professor of Medicine, Pharmacology, Nutritional Science and Public Health at the University of Arizona College of Medicine.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... OR (PRWEB) , ... January 16, 2017 , ... ... author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading ... Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... (iaedp) organized to provide first-quality education and high-level training standards to an international ... spectrum of eating disorder problems. As a way to further its mission at ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... the latest in 3-D scanning device which is capable of taking digital impressions of ... in dentistry, such as CAD CAM restorations , in terms of speed, efficiency ...
(Date:1/16/2017)... , ... January 16, 2017 , ... NexTec Group has ... group of 100 organizations honored for their accomplishments in the field of midmarket financial ... industry leadership and recognition, and innovation. Selection is not based on revenue and those ...
(Date:1/15/2017)... CINCINNATI, Ohio (PRWEB) , ... January 15, 2017 ... ... their applications, Gensuite’s Community Outreach is a program that strives to better communities ... in each global locations’ community. It also provides the opportunity for team members ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... , January 13, 2017 Constant research ... AIDS will collectively contribute to the demand for western blotting ... a value of US$ 551.0 Mn by 2016 end. Developing ... the most lucrative markets for western blotting, whereas ... globally. ...
(Date:1/13/2017)... YORK , January 13, 2017 ... equities to see how they have fared at yesterday,s ... ), Galena Biopharma Inc. (NASDAQ: GALE ), ... These companies harness cellular and biomolecular processes to develop ... reduce our environmental footprint, feed the hungry, use less ...
Breaking Medicine Technology: